Physician profile
Sareena Malhi
NPI 1578597522
$843.00
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $843.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $224.17 | 2019 | |
| Exelixis INC. | $88.87 | 2019 | |
| Genzyme Corporation | $83.06 | 2019 | |
| Daiichi Sankyo INC. | $61.73 | 2019 | |
| Merck Sharp & Dohme LLC | $49.04 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $46.80 | 2019 | |
| Abbvie INC. | $45.87 | 2019 | |
| Tesaro, INC. | $39.38 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $31.96 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.71 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $24.93 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $21.06 | 2019 | |
| Clovis Oncology, INC. | $18.33 | 2019 | |
| Dendreon Pharmaceuticals LLC | $16.16 | 2019 | |
| Janssen Biotech, INC. | $13.16 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $13.12 | 2019 | |
| Gilead Sciences, INC. | $12.94 | 2019 | |
| Amag Pharmaceuticals, INC. | $12.80 | 2019 | |
| Seagen INC. | $11.91 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sareena Malhi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.